Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials

PURPOSE: Although biomarkers for patients with metastatic colorectal cancer exist, the benefit patients with RAS mutated tumors derive from established regimens is unclear. METHODS: Efficacy of therapeutic strategies available for RAS mutated patients (addition of chemotherapeutic agents and/or anti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Cancer Res Clin Oncol
Autors principals: Stahler, Arndt, Heinemann, Volker, Ricard, Ingrid, von Einem, Jobst C., Giessen-Jung, Clemens, Westphalen, Christoph Benedikt, Michl, Marlies, Heinrich, Kathrin, Miller-Phillips, Lisa, Jelas, Ivan, Stintzing, Sebastian, Modest, Dominik Paul
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Review – Clinical Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7324435/
https://ncbi.nlm.nih.gov/pubmed/32561975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00432-020-03290-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars